AbbVie plans to share results from another phase 3 trial of tavapadon later this year, the pharma said in the release. That ...

A tremor that won’t stop, slow movements, rigid muscles they’re the classic signs of Parkinson’s disease that alert doctors ...

First Amendment: Congress shall make no law respecting an establishment of religion, or prohibiting the free exercise thereof; or abridging the freedom of speech, or of the press; or the right of the ...

Parkinson's disease (PD), the second most common neurodegenerative disorder globally, has long baffled scientists with its ...

The trial studied two doses of the drug, tavapadon, as a monotherapy in which patients showed a statistically significant ...

A team of scientists led by Prof. Patrik Verstreken (VIB-KU Leuven) has identified a new genetic mutation that may cause a ...

All of a sudden, the health benefits of coffee has become a hot topic. Now comes a new study that suggests people are ...

AbbVie reports positive Phase 3 results for tavapadon, a once-daily treatment for early-stage Parkinson's disease. The drug ...

L-dopa, a common Parkinson's disease treatment, could reduce the burden of frequent injections for patients with wet AMD by ...

Tavapadon, a drug made by AbbVie to treat Parkinson’s disease, met phase 3 TEMPO-1 trial goals treated early Parkinson's disease and improved motor skills, the company reported on Thursday.

Deep brain stimulation is an effective treatment for motor symptoms in patients with movement disorders such as Parkinson's ...

In the TEMPO-1 trial, participants with early PD were randomly assigned to receive tavapadon 5mg or 15mg once daily or placebo.